The true ternary fission, the fission of a nucleus into three fragments of nearly equal mass, is an elusive and poorly known process influenced by shell effects. It has been envisaged an increase of the probability of this process with respect to the binary fission, very low in spontaneous and neutron-induced fission, by adopting heavy-ion induced reactions due to the possibility to increase the fissility parameter and the excitation energy of the compound nuclei. Nuclei with mass number around A=250, accessible in heavy-ion induced reactions, are favorable and should be investigated. It is still debated if the process takes place in a single step, direct ternary fission, or in two steps, sequential ternary fission. The purpose of this work is to define experimental conditions and observables that allow the disentangling of the products from the direct and sequential ternary fission as well as from the usual most probable binary fission. This step is essential to gain insight on the ternary fission dynamics and on the binary to ternary fission competition. The method proposed here is to simulate the kinematics of the ternary and binary fission processes to compute the energy distributions and angular correlations of direct and sequential ternary fission products, as well as those of binary fission. The reaction taken as benchmark is 40Ar+208Pb at 230 MeV supposed to form the 248Fm* compound nucleus. The simulation results have been filtered by considering the response function of a multi-coincidence detection system virtually constructed using the Geant4 simulation toolkit. The simulations support the possibility to separate the products of different multimodal fission decays with the proposed setup that consequently represents an effective tool to get insight on ternary fission from the observables selected.

On-chip spectrometers are increasingly becoming tools that might help in everyday life needs. The possibility offered by the several available integration technologies and materials to be used to miniaturize spectrometers has led to a plethora of very different devices, that in principle can be compared according to their metrics. Having access to a reference database can help in selecting the most performing on-chip spectrometers and to be up-to-date in terms of standards and developments. In this paper, an overview of the most relevant publications available in literature on miniaturized spectrometers is reported and a database is provided as an open-source project to which researchers can have access and participate in order to improve the share of knowledge in the interested scientific community.

Two-Dimensional Nuclear Magnetic Resonance (2D NMR) spectroscopy has become a cornerstone in pharmaceutical research, offering enhanced structural elucidation capabilities for complex molecules. This technique overcomes the limitations of one-dimensional (1D) NMR by providing detailed insights into molecular interactions through the use of advanced spectroscopic methods like COSY, HSQC, and HMBC. In pharmaceutical applications, 2D NMR plays a crucial role in drug characterization, quality control, formulation development, and the structural analysis of natural products. Recent technological advancements such as high-field spectrometers and cryogenic probes have further improved the sensitivity and resolution of 2D NMR, making it indispensable for ensuring drug quality and intellectual property protection. This article delves into the principles and applications of 2D NMR in the pharmaceutical industry, highlighting its critical contributions to drug discovery, development, and quality assurance. Additionally, it addresses the future prospects of 2D NMR in areas like metabolomics, structural biology, and the development of new analytical tools. Despite its numerous advantages, 2D NMR presents challenges such as high operational costs, complexity in data analysis, and sensitivity issues when dealing with low-concentration samples. The article concludes by discussing the ongoing advancements in 2D NMR technology and its evolving role in pharmaceutical innovation.